UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma
Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Toward improving the therapeutic index of standard TT3 (S-TT3), the investigators will employ
a randomized Phase III trial design to determine whether S-TT3 treatment-related toxicities
can be reduced by 50% in TT3-Lite (L-TT3).
Note: Randomization has been discontinued and accrual is closed to the L-TT3 arm. This trial
is currently enrolling as a single-arm trial for patients to receive S-TT3.